Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Mol Cancer Res. 2017 Sep 14;15(12):1741–1751. doi: 10.1158/1541-7786.MCR-17-0010

Figure 3. PRELID1 modulates cell growth response to cellular stress in breast cancer.

Figure 3

A. Growth rates over 48h for MCF-7 (black bars) or MDA-MB-231 (white bars) grown in normal growth media for (left to right) shRNA controls, PRELID1 KD cells, and TRIAP1 KD cells. Relative growth rates are normalized to the shRNA controls. B. Growth rates over 48h for MCF-7 (black bars) or MDA-MB-231 (white bars) grown in media with 0.5% serum, relative to growth rates over 48h in normal media for (left to right) shRNA controls, PRELID1 KD cells, and TRIAP1 KD cells. Relative growth rates are normalized to the shRNA controls. C. Relative cell numbers for MCF-7 PRELID1 KD cells (white bars) or MCF-7 with shRNA controls (black bars) at 48 h, relative to DMSO-treated controls following 4.5 h pulse treatments with Thapsigargin. D. Relative cell numbers for MCF-7 PRELID1 KD cells (white bars) or MCF-7 with shRNA controls (black bars), relative to DMSO-treated controls following 48 h treatments with Docetaxel or Thapsigargin. SRB assays were performed with 8 wells/condition for three separate biological replicates. An unpaired t-test was used to assess significance. *p<0.05, **p<0.01, ***p<0.001